(Image from Lyra Therapeutics)
Lyra Therapeutics (Nasdaq:LYRA) announced today that it entered into an agreement to sell securities in a private placement worth more than 100 million.
The company — which develops the XTreo platform designed to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues — did not list an intended use of proceeds.
Get the full story at our sister site, Drug Delivery Business News.